BERLIN, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 23, 2006--NOXXON Pharma AG (NOXXON) announced today a multi-year global collaboration with Pfizer Inc. (NYSE:PFE) regarding the discovery and development of Spiegelmer products. In addition, the two companies entered into an exclusive worldwide license agreement relating to NOXXON’s preclinical lead Spiegelmer for treating obesity. Under both agreements, Pfizer will make upfront cash payments as well as R & D milestone payments. In addition, NOXXON is eligible to receive royalties on the sale of products commercialized under these agreements. Pfizer will also make an equity investment in NOXXON.
